# A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

> **NCT01101906** · PHASE2 · TERMINATED · sponsor: **Astellas Pharma Inc** · enrollment: 23 (actual)

## Conditions studied

- Advanced Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** OSI-906
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01101906
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01-10
- **Primary completion:** 2011-11-04
- **Final completion:** 2011-12-28
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Company decided not to pursue the development of this drug in this patient population at this time
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01101906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01101906, "A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01101906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*